tiprankstipranks
Trending News
More News >
Sirnaomics Ltd. (HK:2257)
:2257
Hong Kong Market
Advertisement

Sirnaomics Ltd. (2257) AI Stock Analysis

Compare
4 Followers

Top Page

HK:2257

Sirnaomics Ltd.

(2257)

Rating:57Neutral
Price Target:
HK$8.50
▲(5.33% Upside)
The stock's overall score reflects significant financial challenges and a precarious balance sheet, which outweigh the current positive technical momentum. The technical analysis suggests strong upward price trends, but overbought indicators could signal a risk of price correction. Valuation concerns remain due to unprofitability and lack of dividends.

Sirnaomics Ltd. (2257) vs. iShares MSCI Hong Kong ETF (EWH)

Sirnaomics Ltd. Business Overview & Revenue Model

Company DescriptionSirnaomics Ltd., an RNA therapeutics biopharmaceutical company, focuses on the discovery and development of product candidates for indications with medical needs in the United Sates and the People's Republic of China. Its lead product candidates include STP705 for the treatment cutaneous squamous cell carcinoma in situ; basal cell carcinoma; cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; keloid scarless healing, hypertrophic scarring, and fat sculpting. The company's lead product candidates also comprise STP707 to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; metastatic cutaneous squamous cell carcinoma; non-small cell lung cancer; liver fibrosis; and lung fibrosis. It also develops STP355 for the treatment of pan cancer; STP369 to treat head and neck/bladder cancer; STP779 for the treatment of liver/lung/pancreatic cancer; STP902 to treat breast cancer; STP702 for the treatment of influenza; STP908 to treat COVID-19; RIM730 COVID-19 vaccine; STP909 for the treatment of HPV/cervical cancer; and STP122G for thrombotic disorders. In addition, the company is developing STP125G to treat hypertriglyceridemia; STP144G for the treatment of complement-mediated diseases; STP133G for cardiometabolic; and STP155G for the treatment hepatitis B virus. Sirnaomics Ltd. was founded in 2007 and is headquartered in Gaithersburg, Maryland.
How the Company Makes MoneySirnaomics Ltd. makes money primarily through the development and commercialization of its RNAi-based therapeutics. The company's revenue model includes licensing agreements, partnerships, and collaborations with pharmaceutical companies, which provide funding and resources for the development of its drug candidates. These partnerships may involve upfront payments, milestone payments, and royalties on future product sales. Additionally, Sirnaomics may generate revenue from government grants and research funding to support its research and development activities.

Sirnaomics Ltd. Financial Statement Overview

Summary
Sirnaomics Ltd. faces significant financial challenges with persistent operating losses and a weak balance sheet characterized by negative equity. Despite some revenue growth and improvements in free cash flow, the company remains unprofitable with high cash burn, raising concerns about its ability to sustain operations without further financing.
Income Statement
20
Very Negative
The company's income statement reveals ongoing challenges in profitability and revenue growth. Despite an increase in revenue from the previous year, the net profit margin remains deeply negative at -289.0% for 2024, indicating significant losses. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. Although the gross profit margin is positive at 67.4%, it is insufficient to offset the high operating expenses.
Balance Sheet
15
Very Negative
The balance sheet indicates a precarious financial position with negative stockholders' equity, signaling insolvency risk. The debt-to-equity ratio is not meaningful due to negative equity, but the company has managed to maintain a relatively low total debt level. The equity ratio is negative, reflecting a higher liability level than assets, which poses a financial stability risk.
Cash Flow
25
Negative
The cash flow statement shows a significant negative free cash flow, indicating cash burn exceeding income. The operating cash flow to net income ratio is negative, highlighting cash outflows in operations. However, there is a noticeable improvement in free cash flow, which grew positively from 2023 to 2024, suggesting some progress towards better cash management.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.78M397.00K705.00K71.00K0.00
Gross Profit1.20M397.00K705.00K71.00K0.00
EBITDA-31.12M-72.36M-89.02M-55.87M-19.27M
Net Income-51.38M-78.69M-88.30M-213.07M-43.77M
Balance Sheet
Total Assets28.33M75.79M163.93M240.65M110.18M
Cash, Cash Equivalents and Short-Term Investments11.77M43.93M105.23M211.99M103.12M
Total Debt8.06M8.85M10.76M7.04M2.88M
Total Liabilities44.33M51.33M52.37M30.36M204.36M
Stockholders Equity-1.68M40.20M122.01M211.62M-94.43M
Cash Flow
Free Cash Flow-19.84M-72.03M-107.54M-62.85M-21.15M
Operating Cash Flow-19.73M-70.29M-88.71M-56.97M-19.00M
Investing Cash Flow2.14M-5.35M-32.61M-6.04M8.39M
Financing Cash Flow5.82M-5.61M15.89M170.96M100.37M

Sirnaomics Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price8.07
Price Trends
50DMA
5.56
Positive
100DMA
4.36
Positive
200DMA
3.69
Positive
Market Momentum
MACD
0.84
Negative
RSI
63.90
Neutral
STOCH
68.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2257, the sentiment is Positive. The current price of 8.07 is above the 20-day moving average (MA) of 7.14, above the 50-day MA of 5.56, and above the 200-day MA of 3.69, indicating a bullish trend. The MACD of 0.84 indicates Negative momentum. The RSI at 63.90 is Neutral, neither overbought nor oversold. The STOCH value of 68.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2257.

Sirnaomics Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
HK$1.92B48.364.92%38.48%
65
Neutral
¥342.43B8.69-3.93%2.47%11.18%-19.47%
57
Neutral
HK$917.05M-266.90%31.23%
53
Neutral
HK$1.44B-32.59%-79.65%37.50%
52
Neutral
HK$4.01B-75.64%42.21%29.52%
51
Neutral
HK$765.30M
-1.73%-689.53%
49
Neutral
HK$10.84B-22.23%-14.17%76.00%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2257
Sirnaomics Ltd.
8.07
3.75
86.81%
HK:1875
TOT BIOPHARM International Co. Ltd.
2.41
0.46
23.59%
HK:2197
Clover Biopharmaceuticals Ltd.
0.58
0.30
107.14%
HK:2616
CStone Pharmaceuticals
6.92
5.67
453.60%
HK:3681
SinoMab Bioscience Ltd.
3.06
1.47
92.45%
HK:6628
Transcenta Holding Limited
2.99
1.71
133.59%

Sirnaomics Ltd. Corporate Events

Sirnaomics Announces Director Resignation and Plans for Succession
Jul 22, 2025

Sirnaomics Ltd. announced the resignation of Dr. Cheung Hoi Yu from his roles as an independent non-executive director and various committee positions, effective October 18, 2025. Dr. Yu is stepping down to focus on other commitments, and the company is actively seeking suitable candidates to fill the resulting vacancies to maintain compliance with listing regulations.

Sirnaomics Ltd. Strengthens Leadership with New Director Appointments
Jul 3, 2025

Sirnaomics Ltd. has announced the appointment of Mr. Ouyang Yunlong as a non-executive director and Dr. Zhang Peng as an independent non-executive director, both effective from July 3, 2025. These appointments are expected to strengthen the company’s leadership in the biomedical industry, leveraging Mr. Ouyang’s extensive experience in financial management and venture capital investment, and Dr. Zhang’s expertise, to enhance strategic decision-making and industry positioning.

Sirnaomics Ltd. Announces Board of Directors and Their Roles
Jul 3, 2025

Sirnaomics Ltd. has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement underscores the company’s commitment to strong governance and strategic leadership, which could enhance its position in the biotechnology sector and potentially impact its stakeholders positively.

Sirnaomics Ltd. AGM Resolutions Passed, Paving Way for Strategic Growth
Jun 20, 2025

Sirnaomics Ltd. announced the successful passing of all resolutions at its Annual General Meeting held on June 20, 2025. Key decisions included the re-election of directors, re-appointment of auditors, and granting mandates for share issuance and buybacks, reflecting strong shareholder support and strategic positioning for future growth.

Sirnaomics Ltd. Announces Board Composition and Committee Roles
Jun 20, 2025

Sirnaomics Ltd. has announced the composition of its board of directors, highlighting key roles and committee memberships. The board includes Dr. Poon Hung Fai as the CEO and executive director, with Ms. Monin Ung serving as the chairlady. The announcement also details the structure of the company’s audit, nomination, and remuneration committees, which are crucial for corporate governance and strategic decision-making.

Sirnaomics Ltd. Updates Nomination Committee Terms
Jun 5, 2025

Sirnaomics Ltd. has amended the terms of reference for its Nomination Committee, initially adopted in December 2021. The committee, which plays a crucial role in the governance of the company, is composed of at least three directors, with a majority being independent non-executive directors and at least one member of a different gender. This amendment underscores the company’s commitment to diversity and effective governance, potentially enhancing its industry positioning and stakeholder confidence.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 26, 2025